JPRN-UMIN000040442已完成未知
Effects of Luseogliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes and Established Cardiovascular Disease - Effects of Luseogliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Saiseikai Fukuoka General Hospital0 个研究点目标入组 25 人开始时间: 2020年5月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •already taking an SGLT2 inhibitor, age < 30 years or >= 75 years, diagnosis of type 1 diabetes or insulin-dependent diabetes, symptomatic heart failure (NYHA II-IV), severe renal dysfunction (eGFR < 45 mL/min/1.73 m2), severe liver dysfunction (over 3* upper limit of normal), diabetic ketoacidosis or diabetic coma the presence of malignancy.
研究者
相似试验
招募中
4 期
TOP-HFPEF trialHeart failure with preserved ejection fraction in type 2 diabetes mellitusheart failure with preserved ejection fraction, type 2 diabetesJPRN-jRCTs051210084Kitakaze Masafumi90
已完成
不适用
Impact of Dapagliflozin on Left ventricular hemodynamics and Exercise-induced Pulmonary hypertension evaluated by echocardiography in patients with type 2 diabetes; an open-label prospective randomized controlled trialJPRN-UMIN000023834The Japan Society for Patient Reported Outcome78
招募中
不适用
ucent-J StudyJPRN-jRCTs051220016Tamanaha Tamiko40
尚未招募
Unknown
The Impact of Empagliflozin on Left Ventricular Myocardial Stiffness in Heart Failure with Preserved Ejection FractioPatients with heart failure with preserved ejecion fraction (HFpEF)Drug intervention, Empagliflozin, Pressure-Volume LoopHFpEF/I509JPRN-jRCTs071230020Hieda Michinari38
已完成
4 期
The effect of Pioglitazone on Cardiovascular and Psychiatric status of non-Diabetic Metabolic Syndrome PatientsMetabolic Syndrome.Metabolic disorder, unspecifiedIRCT201101023733N2Osvah Pharmaceutical Company140